Advertisement

Are Non-steroidal Anti-Inflammatory Drugs Clinically Suitable for the Treatment of Symptoms in Depression-Associated Inflammation?

  • Bernhard T. Baune
Part of the Current Topics in Behavioral Neurosciences book series (CTBN, volume 31)

Abstract

The aetiology and pathophysiology of depression have long been associated with inflammation, at least in a proportion of patients. Altered cytokine activity in the periphery and in the brain has brought support to a concept of depression-associated inflammation. However, these immunological changes – and inflammation in particular – in depression have only been recently targeted for treatment. Non-steroidal anti-inflammatory drugs (NSAIDs) have been proposed to be of clinical use in the treatment of depression either as monotherapy or as adjuncts in combination with antidepressants. Specifically, selective cyclooxygenase (COX)-2 and non-selective COX inhibitor NSAIDs as adjuncts or monotherapy have been trialled clinically. A limited body of clinical research has been conducted with mixed results so far. Although meta-analyses appear to support the use of NSAIDs in acute depression, the overall effect is mainly biased by the effects of celecoxib for which the best evidence exists to date. Efficacy data of non-selective COX inhibitor NSAIDs on depressive symptoms is limited and out of six studies, only a retrospective analysis shows positive results for non-selective COX inhibitor. Clinical data on aspirin, an irreversible inhibitor of both COX-1 and COX-2, are mainly experimental and hypothetical at this stage, but may be promising in depressed patients with concomitant inflammatory conditions. The main problematic factor is that current evidence rests on trials in acute depression. Because of the dynamic nature of depression, it is important exploring if NSAIDs and other anti-inflammatory treatments may have a preventive role in early stages of depression and for relapse prevention. The possible impact of anti-inflammatory treatments on immune changes in different phases of depression warrants caution for a wide and preventive use of anti-inflammatory agents in depression-associated inflammation.

Keywords

Depression-associated inflammations Non-steroidal anti-inflammatory drugs Phases of depression Prevention 

References

  1. 1.
    Musil R, Schwarz MJ, Riedel M et al (2011) Elevated macrophage migration inhibitory factor and decreased transforming growth factor-beta levels in major depression—no influence of celecoxib treatment. J Affect Disord 134:217–225CrossRefPubMedGoogle Scholar
  2. 2.
    Howren MB, Lamkin DM, Suls J (2009) Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 71:171–186CrossRefPubMedGoogle Scholar
  3. 3.
    Liu S, Wang X, Li Y et al (2014) Necroptosis mediates TNF-induced toxicity of hippocampal neurons. Biomed Res Int 2014:290182PubMedPubMedCentralGoogle Scholar
  4. 4.
    Uher R, Carver S, Power RA et al (2012) Non-steroidal anti-inflammatory drugs and efficacy of antidepressants in major depressive disorder. Psychol Med 1–9Google Scholar
  5. 5.
    Rush AJ, Trivedi MH, Wisniewski SR et al (2006) Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354:1231–1242CrossRefPubMedGoogle Scholar
  6. 6.
    Setiawan E, Wilson AA, Mizrahi R et al (2015) Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry 72:268–275CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Dowlati Y, Herrmann N, Swardfager W et al (2010) A meta-analysis of cytokines in major depression. Biol Psychiatry 67:446–457CrossRefPubMedGoogle Scholar
  8. 8.
    Haroon E, Raison CL, Miller AH (2012) Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 37:137–162CrossRefPubMedGoogle Scholar
  9. 9.
    Kent S, Bluthe RM, Kelley KW et al (1992) Sickness behavior as a new target for drug development. Trends Pharmacol Sci 13:24–28CrossRefPubMedGoogle Scholar
  10. 10.
    March J, Silva S, Petrycki S et al (2004) Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 292:807–820CrossRefPubMedGoogle Scholar
  11. 11.
    Hannestad J, Dellagioia N, Bloch M (2011) The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 36:2452–2459CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Kim SJ, Li J (2013) Caspase blockade induces RIP3-mediated programmed necrosis in Toll-like receptor-activated microglia. Cell Death Dis 4, e716CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Capuron L, Ravaud A (1999) Prediction of the depressive effects of interferon alfa therapy by the patient’s initial affective state. N Engl J Med 340:1370CrossRefPubMedGoogle Scholar
  14. 14.
    Mendlewicz J, Kriwin P, Oswald P et al (2006) Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. Int Clin Psychopharmacol 21:227–231CrossRefPubMedGoogle Scholar
  15. 15.
    Rush AJ, Trivedi MH, Wisniewski SR et al (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163:1905–1917CrossRefPubMedGoogle Scholar
  16. 16.
    Pasco JA, Jacka FN, Williams LJ et al (2010) Clinical implications of the cytokine hypothesis of depression: the association between use of statins and aspirin and the risk of major depression. Psychother Psychosom 79:323–325CrossRefPubMedGoogle Scholar
  17. 17.
    Rosenstein DL, Lerner D, Cai J (1999) More on the depressive effects of interferon alfa. N Engl J Med 341:849–850CrossRefPubMedGoogle Scholar
  18. 18.
    Terrando N, Monaco C, Ma D et al (2010) Tumor necrosis factor-alpha triggers a cytokine cascade yielding postoperative cognitive decline. Proc Natl Acad Sci U S A 107:20518–20522CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Stellwagen D, Beattie EC, Seo JY et al (2005) Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J Neurosci 25:3219–3228CrossRefPubMedGoogle Scholar
  20. 20.
    Mcdonald EM, Mann AH, Thomas HC (1987) Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers. Lancet 2:1175–1178CrossRefPubMedGoogle Scholar
  21. 21.
    Dantzer R, O’connor JC, Freund GG et al (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9:46–56CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Eyre H, Baune BT (2012) Neuroplastic changes in depression: a role for the immune system. PsychoneuroendocrinologyGoogle Scholar
  23. 23.
    Holtzheimer PE, Meeks TW, Kelley ME et al (2008) A double blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression. Int J Geriatr Psychiatry 23:625–631CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Miller GE, Cole SW (2012) Clustering of depression and inflammation in adolescents previously exposed to childhood adversity. Biol Psychiatry 72:34–40CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Eyre HA, Stuart M, Baune BT (2014) A phase-specific neuroimmune model of depression. Prog Neuro-Psychopharmacol Biol Psychiatry 54:265–274CrossRefGoogle Scholar
  26. 26.
    Lewinsohn PM, Rohde P, Seeley JR et al (2000) Natural course of adolescent major depressive disorder in a community sample: predictors of recurrence in young adults. Am J Psychiatry 157:1584–1591CrossRefPubMedGoogle Scholar
  27. 27.
    Muller N (2013) The role of anti-inflammatory treatment in psychiatric disorders. Psychiatr Danub 25:292–298PubMedGoogle Scholar
  28. 28.
    Shelton RC (2012) Does concomitant use of NSAIDs reduce the effectiveness of antidepressants? Am J Psychiatry 169:1012–1015CrossRefPubMedGoogle Scholar
  29. 29.
    Fava GA, Ruini C, Belaise C (2007) The concept of recovery in major depression. Psychol Med 37:307–317CrossRefPubMedGoogle Scholar
  30. 30.
    Peschon JJ, Torrance DS, Stocking KL et al (1998) TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 160:943–952PubMedGoogle Scholar
  31. 31.
    Akhondzadeh S, Jafari S, Raisi F et al (2009) Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 26:607–611CrossRefPubMedGoogle Scholar
  32. 32.
    Almeida OP, Alfonso H, Jamrozik K et al (2010) Aspirin use, depression, and cognitive impairment in later life: the health in men study. J Am Geriatr Soc 58:990–992CrossRefPubMedGoogle Scholar
  33. 33.
    Almeida OP, Flicker L, Yeap BB et al (2012) Aspirin decreases the risk of depression in older men with high plasma homocysteine. Transl Psychiatry 2, e151CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Fond G, Hamdani N, Kapczinski F et al (2013) Effectiveness and tolerance of anti-inflammatory drugs’ add-on therapy in major mental disorders: a systematic qualitative review. Acta Psychiatr ScandGoogle Scholar
  35. 35.
    Galecki P, Florkowski A, Bienkiewicz M et al (2010) Functional polymorphism of cyclooxygenase-2 gene (G-765C) in depressive patients. Neuropsychobiology 62:116–120CrossRefPubMedGoogle Scholar
  36. 36.
    Golan H, Levav T, Mendelsohn A et al (2004) Involvement of tumor necrosis factor alpha in hippocampal development and function. Cereb Cortex 14:97–105CrossRefPubMedGoogle Scholar
  37. 37.
    Muller N, Schwarz MJ, Dehning S et al (2006) The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 11:680–684CrossRefPubMedGoogle Scholar
  38. 38.
    Murray CJ, Vos T, Lozano R et al (2012) Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2197–2223CrossRefPubMedGoogle Scholar
  39. 39.
    Na KS, Lee KJ, Lee JS et al (2013) Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 48C:79–85Google Scholar
  40. 40.
    O’brien SM, Scott LV, Dinan TG (2004) Cytokines: abnormalities in major depression and implications for pharmacological treatment. Hum Psychopharmacol 19:397–403CrossRefPubMedGoogle Scholar
  41. 41.
    Peng L, Verkhratsky A, Gu L et al (2015) Targeting astrocytes in major depression. Expert Rev Neurother 15:1299–1306CrossRefPubMedGoogle Scholar
  42. 42.
    Song C (2002) The effect of thymectomy and IL-1 on memory: implications for the relationship between immunity and depression. Brain Behav Immun 16:557–568CrossRefPubMedGoogle Scholar
  43. 43.
    Warner-Schmidt JL, Vanover KE, Chen EY et al (2011) Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc Natl Acad Sci U S A 108:9262–9267CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Zhou W, Yuan J (2014) Necroptosis in health and diseases. Semin Cell Dev BiolGoogle Scholar
  45. 45.
    Davis A, Gilhooley M, Agius M (2010) Using non-steroidal anti-inflammatory drugs in the treatment of depression. Psychiatr Danub 22(Suppl 1):S49–S52PubMedGoogle Scholar
  46. 46.
    Maes M, Bosmans E, De Jongh R et al (1997) Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 9:853–858CrossRefPubMedGoogle Scholar
  47. 47.
    Galecki P, Galecka E, Maes M et al (2012) The expression of genes encoding for COX-2, MPO, iNOS, and sPLA2-IIA in patients with recurrent depressive disorder. J Affect Disord 138:360–366CrossRefPubMedGoogle Scholar
  48. 48.
    Galecki P, Szemraj J, Bienkiewicz M et al (2009) Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients. Hum Psychopharmacol 24:277–286CrossRefPubMedGoogle Scholar
  49. 49.
    Aid S, Bosetti F (2011) Targeting cyclooxygenases-1 and -2 in neuroinflammation: therapeutic implications. Biochimie 93:46–51CrossRefPubMedGoogle Scholar
  50. 50.
    Berk M, Dean O, Drexhage H et al (2013) Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness. BMC Med 11:74CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Nery FG, Monkul ES, Hatch JP et al (2008) Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol 23:87–94CrossRefPubMedGoogle Scholar
  52. 52.
    Aid S, Langenbach R, Bosetti F (2008) Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase-2. J Neuroinflammation 5:17CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Choi SH, Aid S, Choi U et al (2010) Cyclooxygenases-1 and -2 differentially modulate leukocyte recruitment into the inflamed brain. Pharmacogenomics J 10:448–457CrossRefPubMedGoogle Scholar
  54. 54.
    Miller AH, Maletic V, Raison CL (2009) Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 65:732–741CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Gallagher PJ, Castro V, Fava M et al (2012) Antidepressant response in patients with major depression exposed to NSAIDs: a pharmacovigilance study. Am J Psychiatry 169:1065–1072CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Haapakoski R, Mathieu J, Ebmeier KP et al (2015) Cumulative meta-analysis of interleukins 6 and 1beta, tumour necrosis factor alpha and C-reactive protein in patients with major depressive disorder. Brain Behav Immun 49:206–215CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Toben C, Baune BT (2015) An act of balance between adaptive and maladaptive immunity in depression: a role for T lymphocytes. J Neuroimmune Pharmacol 10:595–609CrossRefPubMedGoogle Scholar
  58. 58.
    Couch Y, Anthony DC, Dolgov O et al (2013) Microglial activation, increased TNF and SERT expression in the prefrontal cortex define stress-altered behaviour in mice susceptible to anhedonia. Brain Behav Immun 29:136–146CrossRefPubMedGoogle Scholar
  59. 59.
    Moylan S, Maes M, Wray NR et al (2012) The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol PsychiatryGoogle Scholar
  60. 60.
    Trivedi MH, Rush AJ, Wisniewski SR et al (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163:28–40CrossRefPubMedGoogle Scholar
  61. 61.
    Camara ML, Corrigan F, Jaehne EJ et al (2014) Effects of centrally administered etanercept on behavior, microglia, and astrocytes in mice following a peripheral immune challenge. NeuropsychopharmacologyGoogle Scholar
  62. 62.
    Baune BT, Wiede F, Braun A et al (2008) Cognitive dysfunction in mice deficient for TNF- and its receptors. Am J Med Genet B Neuropsychiatr Genet 147B:1056–1064CrossRefPubMedGoogle Scholar
  63. 63.
    Group AI (2013) Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. Contemp Clin Trials 36:555–564CrossRefGoogle Scholar
  64. 64.
    Beattie EC, Stellwagen D, Morishita W et al (2002) Control of synaptic strength by glial TNFalpha. Science 295:2282–2285CrossRefPubMedGoogle Scholar
  65. 65.
    Szelenyi J, Vizi ES (2007) The catecholamine cytokine balance: interaction between the brain and the immune system. Ann N Y Acad Sci 1113:311–324CrossRefPubMedGoogle Scholar
  66. 66.
    Maes M (2012) Targeting cyclooxygenase-2 in depression is not a viable therapeutic approach and may even aggravate the pathophysiology underpinning depression. Metab Brain Dis 27:405–413CrossRefPubMedGoogle Scholar
  67. 67.
    Pollmacher T, Haack M, Schuld A et al (2002) Low levels of circulating inflammatory cytokines—do they affect human brain functions? Brain Behav Immun 16:525–532CrossRefPubMedGoogle Scholar
  68. 68.
    Dunner DL, Rush AJ, Russell JM et al (2006) Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. J Clin Psychiatry 67:688–695CrossRefPubMedGoogle Scholar
  69. 69.
    Zhu L, Bi W, Lu D et al (2014) Regulation of ubiquitin-specific processing protease 8 suppresses neuroinflammation. Mol Cell NeurosciGoogle Scholar
  70. 70.
    Kohler O, Benros ME, Nordentoft M et al (2014) Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 71:1381–1391CrossRefPubMedGoogle Scholar
  71. 71.
    Longhi L, Ortolano F, Zanier ER et al (2008) Effect of traumatic brain injury on cognitive function in mice lacking p55 and p75 tumor necrosis factor receptors. Acta Neurochir Suppl 102:409–413CrossRefPubMedGoogle Scholar
  72. 72.
    Eyre H, Air T, Proctor S et al (2015) A critical review of the efficacy of non-steroidal antiinflammatory drugs in depression. Prog Neuro-Psychopharmacol Biol Psychiatry 57:11–16CrossRefGoogle Scholar
  73. 73.
    Mcafoose J, Baune BT (2009) Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev 33:355–366CrossRefPubMedGoogle Scholar
  74. 74.
    Licinio J (2011) Translational psychiatry: leading the transition from the cesspool of devastation to a place where the grass is really greener. Transl Psychiatry 1, e1CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Conradi HJ, Ormel J, De Jonge P (2011) Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol Med 41:1165–1174CrossRefPubMedGoogle Scholar
  76. 76.
    Fields C, Drye L, Vaidya V et al (2011) Celecoxib or naproxen treatment does not benefit depressive symptoms in persons age 70 and older: findings from a randomized controlled trial. Am J Geriatr PsychiatryGoogle Scholar
  77. 77.
    Eyre HA, Stuart MJ, Baune BT (2014) A phase-specific neuroimmune model of clinical depression. Prog Neuropsychopharmacol Biol Psychiatry 54:265–274CrossRefPubMedGoogle Scholar
  78. 78.
    Eyre H, Baune BT (2012) Neuroplastic changes in depression: a role for the immune system. Psychoneuroendocrinology 37:1397–1416CrossRefPubMedGoogle Scholar
  79. 79.
    Leonard B, Maes M (2012) Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 36:764–785CrossRefPubMedGoogle Scholar
  80. 80.
    Auriel E, Regev K, Korczyn AD (2014) Nonsteroidal anti-inflammatory drugs exposure and the central nervous system. Handb Clin Neurol 119:577–584CrossRefPubMedGoogle Scholar
  81. 81.
    Tobinick EL, Gross H (2008) Rapid cognitive improvement in Alzheimer’s disease following perispinal etanercept administration. J Neuroinflammation 5:2CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Discipline of Psychiatry, School of MedicineUniversity of AdelaideAdelaideAustralia

Personalised recommendations